share_log

OmniAb (NASDAQ:OABI) Coverage Initiated at Truist Financial

OmniAb (NASDAQ:OABI) Coverage Initiated at Truist Financial

在真理財經開始的 Omniab（納斯達克：OABI）覆蓋範圍
Financial News Live ·  2022/12/22 02:51

Equities research analysts at Truist Financial initiated coverage on shares of OmniAb (NASDAQ:OABI – Get Rating) in a report released on Tuesday, The Fly reports. The brokerage set a "buy" rating and a $10.00 price target on the stock. Truist Financial's target price would indicate a potential upside of 159.07% from the stock's current price.

據The Fly報道，Truist Financial的股票研究分析師在週二發佈的一份報告中發起了對OmniAb(納斯達克：OABI-GET評級)股票的報道。該經紀公司為該股設定了“買入”評級和10.00美元的目標價。Truist Financial的目標價顯示，該股較當前股價有159.07%的潛在上漲空間。

Several other equities research analysts have also recently issued reports on OABI. Credit Suisse Group started coverage on shares of OmniAb in a research note on Friday, December 16th. They set an "outperform" rating and a $13.00 price target on the stock. SVB Leerink started coverage on shares of OmniAb in a research report on Tuesday, November 29th. They issued an "outperform" rating and a $6.00 target price on the stock. Finally, Stifel Nicolaus started coverage on shares of OmniAb in a research report on Monday, November 28th. They issued a "buy" rating and a $12.00 target price on the stock.

其他幾位股票研究分析師最近也發佈了關於OABI的報告。瑞士信貸集團在12月16日星期五的一份研究報告中開始報道OmniAb的股票。他們為該股設定了“跑贏大盤”的評級和13.00美元的目標價。SVB Leerink在11月29日星期二的一份研究報告中開始報道OmniAb的股票。他們對該股的評級為“跑贏大盤”，目標價為6.00美元。最後，Stifel Nicolaus在11月28日星期一的一份研究報告中開始報道OmniAb的股票。他們對該股的評級為“買入”，目標價為12美元。

Get
到達
OmniAb
OmniAb
alerts:
警報：

OmniAb Trading Up 17.0 %

OmniAb交易上漲17.0%

OmniAb stock opened at $3.86 on Tuesday. OmniAb has a 12-month low of $1.91 and a 12-month high of $10.50.

OmniAb的股票週二開盤報3.86美元。OmniAb的12個月低點為1.91美元，12個月高位為10.50美元。

Insider Activity

內幕活動

In other news, CEO Matthew W. Foehr acquired 300,000 shares of the company's stock in a transaction dated Wednesday, November 30th. The shares were bought at an average price of $3.39 per share, for a total transaction of $1,017,000.00. Following the completion of the purchase, the chief executive officer now directly owns 1,705,350 shares of the company's stock, valued at approximately $5,781,136.50. The transaction was disclosed in a filing with the SEC, which is available at
在其他新聞方面，首席執行官馬修·W·福爾在11月30日星期三的一筆交易中收購了30萬股該公司股票。這些股票是以每股3.39美元的平均價格購買的，總交易額為1,017,000.00美元。收購完成後，首席執行官現在直接擁有1,705,350股公司股票，價值約5,781,136.50美元。這筆交易是在提交給美國證券交易委員會的一份檔案中披露的，該檔案可在
this hyperlink
此超鏈接
. In other news, CEO Matthew W. Foehr acquired 300,000 shares of the company's stock in a transaction dated Wednesday, November 30th. The shares were bought at an average price of $3.39 per share, for a total transaction of $1,017,000.00. Following the completion of the purchase, the chief executive officer now directly owns 1,705,350 shares of the company's stock, valued at approximately $5,781,136.50. The transaction was disclosed in a filing with the SEC, which is available at
。在其他新聞方面，首席執行官馬修·W·福爾在11月30日星期三的一筆交易中收購了30萬股該公司股票。這些股票是以每股3.39美元的平均價格購買的，總交易額為1,017,000.00美元。收購完成後，首席執行官現在直接擁有1,705,350股公司股票，價值約5,781,136.50美元。這筆交易是在提交給美國證券交易委員會的一份檔案中披露的，該檔案可在
this hyperlink
此超鏈接
. Also, CEO Matthew W. Foehr purchased 150,000 shares of the company's stock in a transaction that occurred on Monday, December 12th. The stock was bought at an average price of $3.77 per share, with a total value of $565,500.00. Following the purchase, the chief executive officer now owns 1,838,084 shares of the company's stock, valued at approximately $6,929,576.68. The disclosure for this purchase can be found
。此外，首席執行官馬修·W·福爾在12月12日(星期一)的一次交易中購買了15萬股公司股票。這只股票是以每股3.77美元的平均價格購買的，總價值為565,500.00美元。收購後，這位首席執行官現在擁有1,838,084股公司股票，價值約6,929,576.68美元。關於這次購買的披露可以找到
here
這裡
. Insiders have bought 482,250 shares of company stock worth $1,694,038 over the last 90 days.
。在過去的90天裡，內部人士購買了482,250股公司股票，價值1,694,038美元。

About OmniAb

關於OmniAb.

(Get Rating)

(獲取評級)

OmniAb, Inc, a biotechnology company, provides therapeutic antibody discovery technologies in the United States. The company's discovery platform provides industry partners access to the diverse antibody repertoires and screening technologies to enable discovery of next-generation therapeutics. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates.

OmniAbInc.是一家生物技術公司，在美國提供治療性抗體發現技術。該公司的發現平臺為行業合作夥伴提供了訪問各種抗體譜系和篩選技術的機會，以實現下一代療法的發現。它的OmniAbPlatform是專有轉基因動物的生物智慧，包括Omni大鼠、OmniChicken和OmniMouse，這些動物已經經過基因改造，產生具有人類序列的抗體，以促進人類候選治療的開發。

Featured Stories

專題報道

  • Get a free copy of the StockNews.com research report on OmniAb (OABI)
  • Lucid Motors Faces a Reality That May Cloud a Bullish Perception
  • Institutions Put Bottom In Rite Aid Shares
  • Here's Why You Should Steer Clear of the FedEx Bounce
  • Why Did Viking Therapeutics Stock Skyrocket
  • NIKE, Inc Swooshes Higher On Results And Outlook
  • 免費獲取StockNews.com關於OmniAb的研究報告(OABI)
  • Lucid Motors面臨的現實可能會給看漲的看法蒙上陰影
  • 機構將Rite Aid的股票跌至谷底
  • 這就是為什麼你應該避開聯盟快遞的反彈
  • 維京治療公司股票為何暴漲
  • 耐克公司業績和前景走高

Receive News & Ratings for OmniAb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OmniAb and related companies with MarketBeat.com's FREE daily email newsletter.

接受OmniAbDaily的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊，接收最新新聞和分析師對OmniAb及相關公司的評級的每日摘要。

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論